D-1233-2020 Class II Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1233-2020 was initiated by Aurobindo Pharma USA Inc. on March 18, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed The recall status is terminated (terminated March 25, 2024). Affected quantity: 8040 units.

Recall Details

Product Type
Drugs
Report Date
April 22, 2020
Initiation Date
March 18, 2020
Termination Date
March 25, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
8040 units

Product Description

Levetiracetam Tablets USP 750 mg 120-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520, NDC 65862-247-08

Reason for Recall

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Distribution Pattern

Nationwide within the United States

Code Information

Lot #: 24719001A1, Exp. Date 03/2021